VERNON SUTTON to Treatment Outcome
This is a "connection" page, showing publications VERNON SUTTON has written about Treatment Outcome.
Connection Strength
0.077
-
Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J Bone Miner Res. 2024 Sep 02; 39(9):1215-1228.
Score: 0.018
-
The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII. Mol Genet Metab. 2020 03; 129(3):219-227.
Score: 0.013
-
Megaloblastic Anemia Progressing to Severe Thrombotic Microangiopathy in Patients with Disordered Vitamin B12 Metabolism: Case Reports and Literature Review. J Pediatr. 2018 11; 202:315-319.e2.
Score: 0.012
-
Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study. Am J Med Genet A. 2015 Oct; 167A(10):2272-81.
Score: 0.010
-
State of the art review in hypospadias: challenges in diagnosis and medical management. Pediatr Endocrinol Rev. 2014 Sep; 12(1):46-54.
Score: 0.009
-
Extracorporeal membrane oxygenation support of a severe metabolic crisis in a child with methylmalonic acidemia. ASAIO J. 2012 Jul-Aug; 58(4):438-9.
Score: 0.008
-
Neurologic considerations in propionic acidemia. Mol Genet Metab. 2012 Jan; 105(1):10-5.
Score: 0.007